Alpha-blockers in the treatment of benign prostatic hypertrophy: physiological basis and review of the problem.
After reviewing the pharmacological and physiological basis for the treatment of benign prostatic hypertrophy (BPH) symptoms with alpha 1-adrenergic blockers, the authors analyze the clinical trials published in the literature. The indications, doses, side effects and contraindications for the alpha 1 blockers in the treatment of BPH are summarized.
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007741:Labetalol / Q000627:therapeutic use; D008297:Male; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011942:Receptors, Adrenergic, alpha / Q000502:physiology
D000317:Adrenergic alpha-Antagonists; D011942:Receptors, Adrenergic, alpha; D010643:Phenoxybenzamine; D007741:Labetalol; D011224:Prazosin; D010646:Phentolamine